These findings suggest that while PD-1 blockade and Treg-targeting monotherapy alone have limited effects on tumor cell killing, their combined use may potentially enhance anticancer efficacy by synergistically reactivating immune effector functions in a state of reduced immunosuppression. The gene discussed is PDCD1; the disease is neoplasm.